Literature DB >> 16639747

Structure of a glutathione conjugate bound to the active site of aldose reductase.

Ranvir Singh1, Mark A White, Kota V Ramana, J Mark Petrash, Stanley J Watowich, Aruni Bhatnagar, Satish K Srivastava.   

Abstract

Aldose reductase (AR) is a monomeric NADPH-dependent oxidoreductase that catalyzes the reduction of aldehydes, ketones, and aldo-sugars. AR has been linked to the development of hyperglycemic injury and is a clinical target for the treatment of secondary diabetic complications. In addition to reducing glucose, AR is key regulator of cell signaling through it's reduction of aldehydes derived from lipoproteins and membrane phospholipids. AR catalyzes the reduction of glutathione conjugates of unsaturated aldehydes with higher catalytic efficiency than free aldehydes. The X-ray structure of human AR holoenzyme in complex with the glutathione analogue S-(1,2-dicarboxyethyl) glutathione (DCEG) was determined at a resolution of 1.94 A. The distal carboxylate group of DCEG's dicarboxyethyl moiety interacted with the conserved AR anion binding site residues Tyr48, His110, and Trp111. The bound DCEG's glutathione backbone adopted the low-energy Y-shape form. The C-terminal carboxylate of DCEG glutathione's glycine formed hydrogen bonds to Leu301 and Ser302, while the remaining interactions between DCEG and AR were hydrophobic, permitting significant flexibility of the AR and glutathione (GS) analogue interaction. The observed conformation and interactions of DCEG with AR were consistent with our previously published molecular dynamics model of glutathionyl-propanal binding to AR. The current structure identifies major interactions of glutathione conjugates with the AR active-site residues. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16639747     DOI: 10.1002/prot.20988

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  13 in total

1.  Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor.

Authors:  Hong Zhang; Qiang Huang; Jing Zhai; Yi-ning Zhao; Li-ping Zhang; Yun-yun Chen; Ren-wei Zhang; Qing Li; Xiao-peng Hu
Journal:  Acta Pharmacol Sin       Date:  2015-08-17       Impact factor: 6.150

Review 2.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 3.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

Review 4.  Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders.

Authors:  Satish K Srivastava; Umesh C S Yadav; Aramati B M Reddy; Ashish Saxena; Ravinder Tammali; Mohammad Shoeb; Naseem H Ansari; Aruni Bhatnagar; Mark J Petrash; Sanjay Srivastava; Kota V Ramana
Journal:  Chem Biol Interact       Date:  2011-02-24       Impact factor: 5.192

5.  Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages.

Authors:  Kota V Ramana; Aramati B M Reddy; Ravinder Tammali; Satish K Srivastava
Journal:  Free Radic Biol Med       Date:  2007-01-24       Impact factor: 7.376

6.  ALDOSE REDUCTASE: New Insights for an Old Enzyme.

Authors:  Kota V Ramana
Journal:  Biomol Concepts       Date:  2011-04-01

Review 7.  Aldose reductase: a novel therapeutic target for inflammatory pathologies.

Authors:  Kota V Ramana; Satish K Srivastava
Journal:  Int J Biochem Cell Biol       Date:  2009-09-22       Impact factor: 5.085

8.  Structural analyses of a constitutively active mutant of exchange protein directly activated by cAMP.

Authors:  Mark A White; Sheng Li; Tamara Tsalkova; Fang C Mei; Tong Liu; Virgil L Woods; Xiaodong Cheng
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

Review 9.  Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes.

Authors:  Umesh C S Yadav; Kota V Ramana
Journal:  Oxid Med Cell Longev       Date:  2013-04-17       Impact factor: 6.543

10.  Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1.

Authors:  Mark Andrew White; Natalia Mast; Ingemar Bjorkhem; Eric F Johnson; C David Stout; Irina A Pikuleva
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.